BioSyent Pharma Signs Exclusive Licence & Distribution Agreement for a New Gastrointestinal Health Product Already Approved b...
March 04 2014 - 8:00AM
Marketwired
BioSyent Pharma Signs Exclusive Licence and Distribution Agreement
for a New Gastrointestinal Health Product Already Approved by
Health Canada-2014 Launch Planned
TORONTO, ONTARIO--(Marketwired - Mar 4, 2014) - BioSyent Inc.
(TSX-VENTURE:RX) ("BioSyent") is pleased to announce that its
subsidiary BioSyent Pharma Inc. has signed an exclusive Canadian
Licence and Distribution Agreement with an existing European
partner for a gastrointestinal health product that has already been
approved by Health Canada.
This licence agreement is with the same partner that will be
supplying the women's health product that is being prepared for
launch in the second quarter of this year. The new product has been
approved in several European countries and is being successfully
marketed there.
"Pre-launch preparations have commenced and we are planning for
a Q4 2014 launch of this new gastrointestinal product," said René
Goehrum, BioSyent CEO. "It will be a good complement to both our
existing promotion activities with healthcare practitioners, and to
our Hospital Products group. This product is also a direct
complement to the women's health product which we will be launching
in a couple of months."
Mr. Goehrum continued, "This new agreement brings the total
number of products that BioSyent has licensed from European
partners to five. One is approved and in the market (Cathejell),
two more are already approved and will be launched this year, and
two are in the process of review for approval by Health Canada.
Along with FeraMAX® 150 and FeraMAX® Powder, this brings our total
product portfolio to seven products."
For a direct market quote (15 minute delay) from the TSX Venture
Exchange and other company financial information please visit
www.tmxmoney.com.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol
"RX", BioSyent is a profitable growth oriented specialty
pharmaceutical company which searches the globe to in-license or
acquire innovative pharmaceutical products that have been
successfully developed, are safe and effective, and have a proven
track record of improving the lives of patients and supporting the
healthcare professionals that treat them.
Once a product of interest has been found, BioSyent then
acquires the exclusive rights to the product and manages it through
the Canadian governmental regulatory approval process. Once
approved, BioSyent markets the product throughout Canada.
At the date of this press release the company had 13,626,195
shares issued and outstanding.
This press release may contain information or statements that
are forward-looking. The contents herein represent our judgment, as
at the release date, and are subject to risks and uncertainties
that may cause actual results or outcomes to be materially
different from the forward-looking information or statements.
Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
The TSX Venture
Exchange assumes no responsibility for the accuracy of this release
and neither approves nor disapproves of the same.
BioSyent Inc.Mr. Rene C. GoehrumPresident and CEO(905)
206-0013investors@biosyent.comwww.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2023 to Jul 2024